Dolby Laboratories (DLB) has disclosed a new risk, in the Corporate Activity and Growth category. Dolby Laboratories faces significant business ...
Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from ...
Dolby Laboratories (NYSE:DLB – Get Free Report) will likely be posting its quarterly earnings results after the market closes ...
Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.
CervoMed (CRVO) provided an update on its neflamapimod development program in dementia with Lewy bodies, DLB, as part of an oral presentation ...
A new study published in Alzheimer’s & Dementia highlights a significant step forward in diagnosing Dementia with Lewy Bodies ...
DLB is a #2 (Buy) on the Zacks Rank, with a VGM Score of B. Additionally, the company could be a top pick for growth investors. DLB has a Growth Style Score of B, forecasting year-over-year ...
Reports Q1 revenue $357M, consensus $345.44M. “We are off to a strong start for FY25,” said Kevin Yeaman, President and CEO, Dolby (DLB) ...